Acrivastine

CLINICAL USE

Antihistamine:

  • Symptomatic relief of allergy such ashayfever, urticaria

    DOSE IN NORMAL RENAL FUNCTION

    8 mg 3 times a day

    PHARMACOKINETICS

  • Molecular weight                           :
    348.4
  • %Protein binding                           :
    50
  • %Excreted unchanged in urine     :
    60
  • Volume of distribution (L/kg)       :
    0.6–0.7
  • half-life – normal/ESRD (hrs)      :
    1.5/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : 8 mg twice a day
  • 10 to 20     : 8 mg 1–2 times a day
  • <10           :
    8 mg 1–2 times a day

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :
    Unknown dialysability. Dose as in
    GFR <10 mL/min
  • HD                     :
    Unknown dialysability. Dose as in
    GFR <10 mL/min
  • HDF/high flux   :
    Unknown dialysability. Dose as in
    GFR <10 mL/min
  • CAV/VVHD      :
    Unknown dialysability. Dose as in
    GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antidepressants: MAOIs and tricyclicsincrease the antimuscarinic and sedative
    effects

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Manufacturers do not recommend use in

    patients with significant renal impairment

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia